GLP-1 Series Part 2: Mounjaro persistence beats Ozempic in type II diabetes

Contact sales for details.

Mounjaro has superior persistence compared to Ozempic, especially when indicated to treat type II diabetes, according to Earnest pharmacy claims data. Around 62% of type II diabetes patients on Mounjaro continue on therapy 12 months out from their initial prescription, compared to around 45% for the same cohort of patients on Ozempic. Across both drugs, persistence rates among patients on GLP-1 therapy for obesity is meaningfully lower relative to the type II diabetes cohort. The limited number of patients using Mounjaro off-label for obesity is roughly on par with Ozempic persistence for type II diabetes, hovering around 45% at month 12. Ozempic persistence among obesity users was 35% at the 12 month mark.  

Novo Nordisk’s Wegovy was excluded from this analysis as recurrent supply shortages drove volatility in patients’ ability to remain on therapy. 

Increased adoption of the semaglutide-based GLP-1’s like Mounjaro and Ozempic could also impact consumer markets like restaurants and CPG.

Data Disclaimer:

Results reflect data as of December 7th, 2023 when they were prepared. Current results may have changed due to panel and methodology updates.